41386-38-3

Basic information

• Product Name: ethyl 4-(2-bromoethoxy)benzoate
• Synonyms: Benzoic acid, 4-(2-bromoethoxy)-, ethyl ester; Ethyl 4-(2-Bromoethoxy)benzoate
• CAS NO: 41386-38-3
• Molecular Formula: C₁₁H₁₃BrO₃
• Molecular Weight: 273.1231
• Mol File: 41386-38-3.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 346.954°C at 760 mmHg
• Flash Point: 163.632°C
• Density: 1.383g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.537
• CAS DataBase Reference: ethyl 4-(2-bromoethoxy)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-bromoethoxy)benzoate(41386-38-3)
• EPA Substance Registry System: ethyl 4-(2-bromoethoxy)benzoate(41386-38-3)

Safety Data

• Hazardous Substances Data: 41386-38-3(Hazardous Substances Data)

Upstream product

• 37142-39-5 4-(2-bromoethoxy)benzonitrile 
• 29936-92-3 ethyl 4-(ethoxycarbonyl)phenoxyacetate 
• 30893-58-4 4-(ethoxycarbonyl)phenoxyacetic acid 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 25389-23-5 ethyl 4-(2-hydroxyethoxy)benzoate 
• 106-93-4 ethylene dibromide 

Downstream Products

• 78712-84-2 4-(2-Imidazol-1-yl-ethoxy)-benzoic acid ethyl ester 
• 76529-46-9 Ethyl 4-(2-Thioethoxy)benzoate 
• 85938-29-0 1-acetyl-3-[2-(4-ethoxycarbonylphenoxy)ethyl]-imidazolium iodide 
• 869299-53-6 methyl 1-[2-({4-[(methyloxy)carbonyl]phenyl}oxy)ethyl]-4-nitro-1H-pyrazole-5-carboxylate 
• 869299-54-7 methyl 1-[2-({4-[(methyloxy)carbonyl]phenyl}oxy)ethyl]-4-nitro-1H-pyrazole-3-carboxylate 
• 1352874-97-5 ethyl 4-(2-(4-(2-oxo-2-(thiazol-2-ylamino)ethyl)piperazin-1-yl)ethoxy)benzoate 
• 133311-45-2 ethyl 4-[2-(1-piperazinyl)ethoxy]benzoate 
• 1440956-03-5 C₁₇H₂₅BO₅ 
• 1440956-17-1 ethyl 4-(3,3,3-trifluoropropoxy)benzoate 
• 1440956-48-8 (2-(4-(ethoxycarbonyl)phenoxy)ethyl)boronic acid 
• 50714-69-7 4-(2-Amino-ethoxy)-benzamide 
• 851133-89-6 4-{2-[2-(3,4-dimethoxy-phenyl)-5,7-dimethoxy-4-oxo-4H-chromen-3-yloxy]-ethoxy}-benzoic acid ethyl ester 
• 52660-66-9 4-(2-amino-ethoxy)-benzoic acid 
• 76529-49-2 Ethyl 4-<2-<(1-Methyl-5-nitro-4-imidazolyl)thio>ethoxy>benzoate 

Relevant articles and documents

New chiral monomers for polymer stabilized cholesteric textures

New mesomorphic chiral acrylates were synthesized. Their additions to a nematic liquid crystalline mixture cause the director of the nematogens molecules to adopt a helically twisted orientation. The pitch of the resulting helicoidal structure is determin

Synthesis of some novel pendant-armed cyclen derivatives

A new easy-to-run route to some novel pendant-armed benzene-containing cyclen derivatives is proposed. In this route, the use of potassium carbonate instead of (N,N)-diisopropylethylamine as proton trapper caused a remarkable increase of yields.

HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)

The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.